Skip Navigation

British Medical Bulletin 2004 70(1):29-49; doi:10.1093/bmb/ldh024
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Karayiannis, P.
Right arrow Articles by Thomas, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karayiannis, P.
Right arrow Articles by Thomas, H. C.
Related Collections
Right arrow Infectious Diseases
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published online 31 August 2004

British Medical Bulletin, Vol. 70 © The British Council 2004; all rights reserved

Hepatitis vaccines

Peter Karayiannis, Janice Main and Howard C. Thomas

Department of Medicine A, Faculty of Medicine, St Mary’s Campus, Imperial College, London, UK

Correspondence to: P. Karayiannis, Department of Medicine A, Faculty of Medicine, Division of Medicine, St Mary’s Campus, Imperial College, London W2 1NY, UK. E-mail: p.karayiannis@imperial.ac.uk

The first 150 words of the full text of this article appear below.


   Introduction
 
The field of hepatitis virus vaccination continues to undergo constant change. Safe and effective vaccines are now available for the prevention of hepatitis A virus (HAV) and hepatitis B virus (HBV) infections. However, controversies regarding their use in health programmes continue, and the emergence of HBV vaccine escape mutants continues to provide challenges for vaccine manufacturers. The development of a hepatitis C virus (HCV) vaccine remains a formidable challenge, but there is a more optimistic outlook for the development of a hepatitis E virus (HEV) vaccine.


   Hepatitis A vaccines
 
HAV is an enterally transmitted member of the Picornaviridae, and the only member of the hepatovirus genus. The RNA genome of the virus is single stranded, positive sense and about 7.5 kb long. It contains a single open reading frame (ORF) that encodes the viral polyprotein, which is post-translationally cleaved by a viral protease to yield the components of the capsid, and a range . . . [Full Text of this Article]


   Hepatitis B vaccines
 

   Hepatitis C vaccines
 
Protein vaccines

DNA vaccines

Other approaches

Summary


   Hepatitis D vaccines
 

   Hepatitis E vaccines
 

   Conclusions
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
N. J Beeching
Hepatitis B infections
BMJ, November 6, 2004; 329(7474): 1059 - 1060.
[Full Text] [PDF]